摘要
经典降糖药二甲双胍为2型糖尿病治疗的首选用药,二肽基肽酶-4(dipeptide base peptidase 4,DPP-4)抑制剂作为一种新型的降糖药,可增加体内肠促胰素水平,促进胰岛素分泌,保护β细胞功能。二甲双胍与DPP-4抑制剂互补的降糖机制标志着两者固定剂量复合(fixed dose combinations,FDC)制剂有较好的临床应用前景。多项研究表明,DPP-4抑制剂/二甲双胍FDC制剂可有效降低Hb A1c、空腹血糖及餐后血糖,低血糖发生率低,不增加体重,而且可提高患者的依从性。
The classic medications metformin is the first choice for the treatment of type 2 diabetes. Dipeptide base peptidase 4 （DPP - 4） inhibitors are a new type of drug for curing diabetes, promoting pancreatic hormone levels, promoting insulin secretion, protecting the function of β cells. Metformin and DPP-4 inhibitors complimentary mechanism of hypoglycemic marks fixed dose combinations （FDC） preparation has good clinical application prospects. Several studies have shown that DPP-4 inhibitors/metformin FDC preparation can effectively reduce the HbA1c, fasting blood glucose and postprandial blood sugar, lower incidence of hypoglycemia, withnot increasing weight, and can improve the patients＇ compliance.
出处
《药品评价》
CAS
2016年第7期18-23,共6页
Drug Evaluation
